ArticleAntimicrobial agents and chemotherapy2004
Posaconazole is a potent inhibitor of sterol 14alpha-demethylation in yeasts and molds.
Article in Antimicrobial agents and chemotherapy, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 79 citations in OpenAlex.
- Posaconazole Target Attainment in Critically Ill Children: A 15-Year Single-Center Retrospective Analysis.Clinical and translational science · 2026Article
- Article
- Recommendations on the use of azole antifungals in hematology-oncology patients.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2023Review
- Electromembrane Extraction of Posaconazole for Matrix-Assisted Laser Desorption/Ionization Mass Spectrometric Detection.Membranes · 2022Article
- Repurposing Antifungals for Host-Directed Antiviral Therapy?Pharmaceuticals (Basel, Switzerland) · 2022Review
- Dendrimer-based posaconazole nanoplatform for antifungal therapy.Drug delivery · 2021Article
- The Overview on the Pharmacokinetic and Pharmacodynamic Interactions of Triazoles.Pharmaceutics · 2021Review
- Influence of Triazole Pesticides on Wine Flavor and Quality Based on Multidimensional Analysis Technology.Molecules (Basel, Switzerland) · 2020Article
- Coumarins: antifungal effectiveness and future therapeutic scope.Molecular diversity · 2020Review
- Sterol Composition of Clinically Relevant Mucorales and Changes Resulting from Posaconazole Treatment.Molecules (Basel, Switzerland) · 2018Article
- Bafilomycin C1 exert antifungal effect through disturbing sterol biosynthesis in Candida albicans.The Journal of antibiotics · 2018Article
- Erg4A and Erg4B Are Required for Conidiation and Azole Resistance via Regulation of Ergosterol Biosynthesis in Aspergillus fumigatus.Applied and environmental microbiology · 2017Article
- Synergistic drug combination effectively blocks Ebola virus infection.Antiviral research · 2017Article
- Trypanosoma brucei CYP51: Essentiality and Targeting Therapy in an Experimental Model.PLoS neglected tropical diseases · 2016Article
- Posaconazole: An Update of Its Clinical Use.Pharmacy (Basel, Switzerland) · 2015Review
- Detection of posaconazole by surface-assisted laser desorption/ionization mass spectrometry with dispersive liquid-liquid microextraction.Journal of the American Society for Mass Spectrometry · 2015Article
- Prevention of invasive fungal infections in immunocompromised patients: the role of delayed-release posaconazole.Infection and drug resistance · 2015Review
- Pharmacokinetics of posaconazole within epithelial cells and fungi: insights into potential mechanisms of action during treatment and prophylaxis.The Journal of infectious diseases · 2013Article
- Role of posaconazole in the treatment of oropharyngeal candidiasis.Infection and drug resistance · 2010Article
- Posaconazole in the management of refractory invasive fungal infections.Therapeutics and clinical risk management · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Posaconazole (POS; SCH 56592) is a novel triazole that is active against a wide variety of fungi, including fluconazole-resistant Candida albicans isolates and fungi that are inherently less susceptible to approved azoles, such as Candida glabrata. In this study, we compared the effects of POS, itraconazole (ITZ), fluconazole (FLZ), and voriconazole (VOR) on sterol biosynthesis in strains of C. albicans (both azole-sensitive and azole-resistant strains), C. glabrata, Aspergillus fumigatus, and Aspergillus flavus. Following exposure to azoles, nonsaponifiable sterols were extracted and resolved by liquid chromatography and sterol identity was confirmed by mass spectroscopy. Ergosterol was the major sterol in all but one of the strains; C. glabrata strain C110 synthesized an unusual sterol in place of ergosterol. Exposure to POS led to a decrease in the total sterol content of all the strains tested. The decrease was accompanied by the accumulation of 14alpha-methylated sterols, supporting the contention that POS inhibits the cytochrome P450 14alpha-demethylase enzyme. The degree of sterol inhibition was dependent on both dose and the susceptibility of the strain tested. POS retained activity against C. albicans isolates with mutated forms of the 14alpha-demethylase that rendered these strains resistant to FLZ, ITZ, and VOR. In addition, POS was a more potent inhibitor of sterol synthesis in A. fumigatus and A. flavus than either ITZ or VOR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.